Dr. Karl Thomae Gmbh

Boehringer Ingelheim Gmbh

Karl Thomae Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Dr. Karl Thomae Gesellschaft MIT Beschrankter Haftung

Other

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Karl Thomas Gmbh

Dr. Karl Thomae Gesellschaft MIT Beschranter Haftung

Wolfhard Engel

Wolfgang Eberlein

Gunter Trummlitz

Gerhard Mihm

Henri Doods

Klaus Rudolf

Ernst Seeger

Gunther Engelhardt

Norbert Mayer

Gunther Schmidt

Rudolf Hammer

Helmut Teufel

Michael Entzeroth

Adriaan De Jonge

Wolfgang Wienen

Josef Nickl

Karl D Hargrave

Piero Del Soldato

Gerhard Hallermayer

Gunther Schmidt, Deceased

Klaus-Dieter Willim

Walter Haarmann

Antonio Giachetti

Gunther Trummlitz

Rainer Zimmermann

Eckhart Bauer

Heike-Andrea Wieland

Gu/ Nther Schmidt

Gu/ Nter Trummlitz

Helmut Pieper

Horst Dollinger

Franz Esser

John Robert Proudfoot

Gerd Schnorrenberg

Karl G Grozinger

Julian Adams

Joachim Kahling

Jurgen Krause

Harald Ziegler

Heike Andrea Wieland

Kurt Schromm

Peter Danneberg

Volker Trach

Gu/ Nther Trummlitz

Piero D Soldato

Adrian De Jonge

Richard Reichl

Vokhard Austel

The present invention relates to modified amino acids of general formula whereinA, Z, X, n, m, R, R, R, Rand Rare defined as in claimsto, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Modified amino acids, pharmaceuticals containing these compounds and method for their production

A compound of general formula (I) wherein R and Rare as defined herein, or a tautomer, diastereomer, enantiomer, or salt thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing the compound, their use, and processes for preparing them.

Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof

The present invention relates to compounds of general formulaR&#x2014;Z&#x2014;Z&#x2014;Z&#x2014;R, &#x2003;&#x2003;(I)wherein

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

A method for treating menopausal hot flushes using CGRP antagonists and/or CGRP release inhibitors and the corresponding pharmaceutical compositions containing as active substance one or more CGRP antagonists and/or CGRP release inhibitors, and the preparation thereof.

Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

Antagonists of calcitonin gene-related peptide

NPY-antagonistic compounds of the formula ##STR1## Exemplary are: (A) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N.sup.2 -bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoracetate;

Amino acid derivatives, pharmaceutical compositions containing these

Amino acid derivatives, medicaments containing said compounds and

Amino acid derivatives, suitable for the treatment of obesity. The following compound is exemplary of the class: (R,S)-N.sup.2 -(diphenylacetyl)-N-�(4-hydroxyphenyl)methyl!-N.sup.5 -(1H-imidazol-2-yl)-ornithinamide.

New condensed diazepinones of general formula I ##STR1## wherein B represents one of the divalent groups ##STR2## and X, l, m, n and R.sup.1 to R.sup.7 are as defined herein, as well as the salts thereof with inorganic or organic acids and processes for preparing them. These compounds are useful for improving or normalising arteriosclerotically induced disorders of cerebral blood flow, for treating diseases of the central nervous system, particularly Alzheimer's disease and Parkinson's disease, and as vagal pacemakers for treating bradycardia and bradyarrhythmia, and also for improving memory performance.

Condensed diazepinones, processes for preparing them and agents

Disclosed are novel 5,11-dihydro-6H-dipyrido[3,2-b; 2',3'-e][1,4]diazepines. These are useful in the prevention or treatment of HIV infection.

5,11-dihyro-6H-dipyrido[3,2-B:2',3'-e][1,3]diazepines and their use in

Amino acid derivatives, suitable for the treatment of obesity. The following compound is exemplary of the class: (R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl) methyl]-argininamide-acetate.

Disclosed is the use of dibenz[b,f][1,4]oxazepin (or thiazepin)-11(10H)-ones and -thiones in the prevention and treatment of AIDS, ARC and related disorders associated with HIV infection.

Dibenz[b,f][1,4]oxazepin(and thiazepin)-11(10H)-ones and-thiones and

Growing community of inventors

Biberach, Germany

Wolfhard Engel